Insmed Research Development from 2010 to 2026

INSM Stock  USD 157.16  3.18  2.07%   
Insmed Research Development yearly trend continues to be very stable with very little volatility. Research Development is likely to grow to about 722.5 M this year. During the period from 2010 to 2026, Insmed Research Development quarterly data regression pattern had sample variance of 62195.5 T and median of  131,711,000. View All Fundamentals
 
Research Development  
First Reported
1999-03-31
Previous Quarter
177.2 M
Current Value
186.4 M
Quarterly Volatility
48.1 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Insmed financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Insmed's main balance sheet or income statement drivers, such as Depreciation And Amortization of 13.3 M, Interest Expense of 102.5 M or Total Revenue of 439.2 M, as well as many indicators such as Price To Sales Ratio of 34.02, Dividend Yield of 0.0 or PTB Ratio of 37.5. Insmed financial statements analysis is a perfect complement when working with Insmed Valuation or Volatility modules.
  
Build AI portfolio with Insmed Stock
Check out the analysis of Insmed Correlation against competitors.
Evaluating Insmed's Research Development across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Insmed Inc's fundamental strength.

Latest Insmed's Research Development Growth Pattern

Below is the plot of the Research Development of Insmed Inc over the last few years. It is Insmed's Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Insmed's overall financial position and show how it may be relating to other accounts over time.
Research Development10 Years Trend
Slightly volatile
   Research Development   
       Timeline  

Insmed Research Development Regression Statistics

Arithmetic Mean245,871,777
Geometric Mean129,090,367
Coefficient Of Variation101.43
Mean Deviation208,830,534
Median131,711,000
Standard Deviation249,390,295
Sample Variance62195.5T
Range716.9M
R-Value0.92
Mean Square Error10444.2T
R-Squared0.84
Slope45,332,788
Total Sum of Squares995128.3T

Insmed Research Development History

2026722.5 M
2025688.1 M
2024598.4 M
2023571 M
2022397.5 M
2021272.7 M
2020181.2 M

About Insmed Financial Statements

Insmed investors utilize fundamental indicators, such as Research Development, to predict how Insmed Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Research Development688.1 M722.5 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Insmed Inc is a strong investment it is important to analyze Insmed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Insmed's future performance. For an informed investment choice regarding Insmed Stock, refer to the following important reports:
Check out the analysis of Insmed Correlation against competitors.
You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Will Biotechnology sector continue expanding? Could Insmed diversify its offerings? Factors like these will boost the valuation of Insmed. Market participants price Insmed higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Insmed data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(6.18)
Revenue Per Share
2.348
Quarterly Revenue Growth
0.524
Return On Assets
(0.28)
Return On Equity
(1.66)
Investors evaluate Insmed Inc using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Insmed's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Insmed's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Insmed's market price signifies the transaction level at which participants voluntarily complete trades.